- Home
- IRMD vs CRGX Comparison
IRMD vs CRGX Comparison
Compare IRMD & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- CRGX
- Stock Information
- Founded
- IRMD 1992
- CRGX 2021
- Country
- IRMD United States
- CRGX United States
- Employees
- IRMD N/A
- CRGX N/A
- Industry
- IRMD Medical/Dental Instruments
- CRGX
- Sector
- IRMD Health Care
- CRGX
- Exchange
- IRMD Nasdaq
- CRGX Nasdaq
- Market Cap
- IRMD 737.7M
- CRGX 621.4M
- IPO Year
- IRMD 2014
- CRGX 2023
- Fundamental
- Price
- IRMD $59.17
- CRGX $12.39
- Analyst Decision
- IRMD Strong Buy
- CRGX Strong Buy
- Analyst Count
- IRMD 1
- CRGX 6
- Target Price
- IRMD $60.00
- CRGX $31.80
- AVG Volume (30 Days)
- IRMD 40.7K
- CRGX 287.3K
- Earning Date
- IRMD 02-06-2025
- CRGX 11-12-2024
- Dividend Yield
- IRMD 1.01%
- CRGX N/A
- EPS Growth
- IRMD 13.16
- CRGX N/A
- EPS
- IRMD 1.46
- CRGX N/A
- Revenue
- IRMD $71,305,130.00
- CRGX N/A
- Revenue This Year
- IRMD $13.29
- CRGX N/A
- Revenue Next Year
- IRMD $10.76
- CRGX N/A
- P/E Ratio
- IRMD $40.53
- CRGX N/A
- Revenue Growth
- IRMD 13.23
- CRGX N/A
- 52 Week Low
- IRMD $40.18
- CRGX $10.91
- 52 Week High
- IRMD $59.31
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- IRMD 67.63
- CRGX 39.66
- Support Level
- IRMD $55.36
- CRGX $10.91
- Resistance Level
- IRMD $59.31
- CRGX $15.75
- Average True Range (ATR)
- IRMD 1.65
- CRGX 1.20
- MACD
- IRMD 0.30
- CRGX -0.11
- Stochastic Oscillator
- IRMD 97.69
- CRGX 30.08
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.